Jae Woon Son

Jae Woon Son is a notable inventor based in Suwon-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in drug delivery systems and purification methods. With a total of 3 patents, his work has the potential to impact various medical treatments.

Latest Patents

One of Jae Woon Son's latest patents is a method for purifying fibrinogen. This method involves several steps, including the precipitation of fibrinogen from a solution using glycine at specific concentrations. The process ensures the recovery of a precipitate through a series of glycine precipitation steps, ultimately leading to a purified solution via nanofiltration.

Another significant patent is a controlled release complex composition that combines angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors. This innovative pharmaceutical composition is designed for delayed release, allowing for different onset times of active ingredients. It is particularly effective in treating hypertension and preventing complications in patients with metabolic syndromes, such as diabetes and obesity.

Career Highlights

Throughout his career, Jae Woon Son has worked with reputable companies in the pharmaceutical industry. Notable among these are Hanall Biopharma Co., Ltd. and Green Cross Holdings Corporation. His experience in these organizations has contributed to his expertise in developing advanced pharmaceutical solutions.

Collaborations

Jae Woon Son has collaborated with several professionals in his field, including Sung Wuk Kim and Sung Soo Jun. These collaborations have likely enhanced his research and development efforts, leading to innovative solutions in pharmaceuticals.

Conclusion

Jae Woon Son is a distinguished inventor whose work in pharmaceutical technologies has the potential to improve medical treatments significantly. His innovative patents reflect his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.